RPA2 and cancer: Consistent with previous findings that greater clonal diversity has been associated with a higher likelihood of therapy-resistant and metastatic subpopulations (51, 52), we found that patients with heterogeneous RAD51 and p-RPA2 staining in their cancers exhibited the worst survival outcomes.